Wealth manager Q&A with Eren Osman: The power of passives
Arbuthnot Latham MD on the profound impact of passives, financial wellbeing and how assessing suitability is still the most important piece of regulation
Author: Portfolio Adviser
-
-
Brooks Macdonald: US small and mid-sized caps are due a comeback
With countries becoming more domestically-oriented and rate cuts on the horizon, Henrietta Walker says US small and mid-caps are back in vogue
-
Alger: Private equity is less appealing than what meets the eye
It has been lauded for its perceived outperformance versus public assets, but Brad Neuman argues it is not so rosy under the bonnet
-
Morningstar: How likely are elections to impact markets?
As half the world heads to the polls, Nick Stanhope examines to what extend markets could react
-
FundCalibre’s McDermott: The UK is a playground for value managers
Value investors in the UK have trumped the trend by beating growth – and the story is far from over, writes Darius McDermott
-
Barclays: Closing the funding gap for female-powered VCs
With female founders losing out on millions in funding, Barclays’ head of business banking calls for the problem to be fixed at its source
-
Kepler: The sectors unscathed by the AI takeover
There is value to be found in the industries immune to the AI revolution, writes Kepler’s Ryan Lightfoot-Aminoff
-
Barings: Glimmers of optimism in EM debt, but risks remain
Opportunities are plentiful in emerging markets this year, but investors should exercise caution, writes Dr Ricardo Adrogue
-
M&G’s Woolnough: Dispersion in bond markets creates opportunities for investors
Richard Woolnough gives his outlook for bonds and how investors can take advantage
-
Morningstar CIO: The shining investment opportunities beyond technology
There are still plenty of undervalued equities to take advantage of despite soaring tech shares, writes Mike Coop
-
SJP: The five areas ultra-high-net-worth investors are allocating
Iain McLeod examines the key trends driving the world’s wealthiest investors’ portfolios
-
WHEB’s Kluftinger: The weight loss industry is a megatrend in the making
Obesity drugs are at a revolutionary moment comparable to the launch of the iPhone, writes Ben Kluftinger